

# Diana A Gorog

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6838803/publications.pdf>

Version: 2024-02-01

114  
papers

2,748  
citations

186265  
28  
h-index

223800  
46  
g-index

118  
all docs

118  
docs citations

118  
times ranked

3380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spontaneous Reperfusion in Patients with Transient ST-Elevation Myocardial Infarctionâ€”Prevalence, Importance and Approaches to Management. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 169-180.	2.6	1
2	RIC in COVID-19â€”a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 925-930.	2.6	3
3	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
4	NETs in the infarct-related coronary artery â€” a marker or mediator of adverse outcome?. <i>Thrombosis and Haemostasis</i> , 2022, , .	3.4	1
5	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	1.7	11
6	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1949-1962.	2.8	36
7	Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial. <i>Cardiovascular Research</i> , 2021, 117, 623-634.	3.8	13
8	Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1-11.	2.1	15
9	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 125-140.	3.0	31
10	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	3.4	149
11	Endogenous fibrinolysisâ€”Relevance to clinical thrombosis risk assessment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13471.	3.4	7
12	2â€”Oxothiazolidineâ€”4â€”carboxylic acid inhibits vascular calcification via induction of glutathione synthesis. <i>Journal of Cellular Physiology</i> , 2021, 236, 2696-2705.	4.1	9
13	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , 2021, 51, 202.	1.9	27
14	Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT Scanning. <i>Critical Care Medicine</i> , 2021, 49, 804-815.	0.9	29
15	Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 595-607.	2.1	65
16	Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1472.	4.1	11
17	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259.	2.2	29
18	Precision Treatment in ACSâ€”Role of Assessing Fibrinolysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 929.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis. American Journal of Cardiology, 2021, 142, 147-151.	1.6	4
20	Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?. SN Applied Sciences, 2021, 3, 1.	2.9	0
21	Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival. American Heart Journal, 2021, 234, 31-41.	2.7	21
22	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal, 2021, 42, 2265-2269.	2.2	81
23	Incidence of thrombotic complications in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 52, 999-1006.	2.1	42
24	Fibrinolysis in Platelet Thrombi. International Journal of Molecular Sciences, 2021, 22, 5135.	4.1	5
25	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal, 2021, 42, 4638-4651.	2.2	80
26	Screening for venous thromboembolism in patients with COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 52, 985-991.	2.1	8
27	Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. Thrombosis and Haemostasis, 2021, , .	3.4	7
28	When a meta-analysis equals a single large-scale trial with meaningful follow-up. European Heart Journal, 2021, 42, 3884-3885.	2.2	3
29	Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?. European Heart Journal, 2021, 42, 3187-3189.	2.2	3
30	Preoperative Atrial Fibrillation is associated with long-term mortality in patients undergoing surgical Aortic valve Replacement. Journal of Cardiac Surgery, 2021, 36, 3561-3566.	0.7	3
31	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiology Journal, 2021, 28, 607-614.	1.2	3
32	Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?. Cardiology Journal, 2021, , .	1.2	6
33	The authors reply. Critical Care Medicine, 2021, Publish Ahead of Print, e1190-e1191.	0.9	2
34	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	1.7	6
35	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovascular Research, 2021, 117, 2705-2729.	3.8	95
36	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal, 2021, , .	1.2	3

#	ARTICLE	IF	CITATIONS
37	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 343-355.	1.0	9
38	Global Thrombosis Test: Occlusion Is Attributable to Shear-Induced Platelet Thrombus Formation. <i>TH Open</i> , 2021, 05, e591-e597.	1.4	0
39	Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics. <i>Thrombosis and Haemostasis</i> , 2020, 120, 008-010.	3.4	1
40	Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 192-198.	2.1	6
41	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	2.2	52
42	Thrombosis Risk with Transcatheter Aortic Valve Replacement. <i>Structural Heart</i> , 2020, 4, 349-359.	0.6	0
43	Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19. <i>European Heart Journal</i> , 2020, 41, 3198-3199.	2.2	18
44	Endovascular thrombectomy 2020: open issues. <i>European Heart Journal Supplements</i> , 2020, 22, M13-M18.	0.1	3
45	Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. <i>European Heart Journal Supplements</i> , 2020, 22, M26-M34.	0.1	5
46	Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. <i>Scientific Reports</i> , 2020, 10, 21379.	3.3	31
47	Peripartum cardiomyopathy: can the link between prolactin and PAI-1 provide a clue?. <i>Cardiovascular Research</i> , 2020, 116, 1791-1793.	3.8	0
48	Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 161-162.	1.6	7
49	Fatal heart block from intentional yew tree ( <i>Taxus baccata</i> ) ingestion: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4.	0.6	8
50	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2020.	2.4	5
51	Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2020, 133, 1328-1335.	1.5	15
52	Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. <i>Thrombosis and Haemostasis</i> , 2020, 120, 565-578.	3.4	20
53	Low-grade endotoxaemia and platelets: a deadly aggregation. <i>European Heart Journal</i> , 2020, 41, 3166-3168.	2.2	4
54	Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 54-62.	4.7	11

#	ARTICLE	IF	CITATIONS
55	MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. <i>European Cardiology Review</i> , 2020, 15, e20.	2.2	12
56	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020, 27, 661-676.	1.2	7
57	Lowering the risk of stroke prevention: Managing bleeding complications. <i>International Journal of Cardiology</i> , 2019, 274, 351-352.	1.7	0
58	Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1785-1794.	3.4	11
59	Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. <i>Journal of Clinical Lipidology</i> , 2019, 13, 788-796.	1.5	7
60	A case of repetitive myocardial infarction with unobstructed coronaries due to Churgâ€“Strauss syndrome. <i>European Heart Journal - Case Reports</i> , 2019, 3, .	0.6	4
61	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 1415-1424.	13.7	223
62	Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. <i>Europace</i> , 2019, 21, 1297-1306.	1.7	20
63	Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1366-1375.	2.8	22
64	Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 392-395.	2.1	8
65	Thrombotic Profile and Oral Anticoagulation in Asian and Non-Asian Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2822-2824.	2.8	6
66	Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. <i>European Heart Journal</i> , 2019, 40, 295-305.	2.2	61
67	Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis. <i>Thrombosis Research</i> , 2019, 173, 102-108.	1.7	16
68	Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size. <i>Thrombosis and Haemostasis</i> , 2018, 118, 601-612.	3.4	34
69	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapyâ€“Current Data and Future Directions. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	11
70	Potential of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 593-602.	2.1	6
71	METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectoriSâ€“The METAMORPHOSIS Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2126-2133.	3.4	39
72	A rare cause of myocardial infarction with non-obstructive coronary arteriesâ€“case report of ST-segment elevation myocardial infarction caused by a mediastinal mass. <i>European Heart Journal - Case Reports</i> , 2018, 2, yty008.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. Vascular Health and Risk Management, 2018, Volume 14, 13-21.	2.3	17
74	Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox. Current Vascular Pharmacology, 2018, 16, 477-483.	1.7	9
75	Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?. Current Vascular Pharmacology, 2018, 16, 427-436.	1.7	1
76	Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 20-27.	2.0	5
77	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 221-234.	3.0	43
78	Allopurinol as a therapeutic option in cardiovascular disease. , 2017, 172, 139-150.		69
79	Percutaneous coronary intervention with drug-eluting stent versus coronary artery bypass grafting: A meta-analysis of patients with left main coronary artery disease. International Journal of Cardiology, 2017, 249, 101-106.	1.7	2
80	Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis. Journal of Thrombosis and Thrombolysis, 2017, 44, 413-426.	2.1	8
81	Arterial Thrombus Stability. Journal of the American College of Cardiology, 2017, 70, 2036-2047.	2.8	48
82	“Mind the gap” acute coronary syndrome in women: A contemporary review of current clinical evidence. International Journal of Cardiology, 2017, 227, 840-849.	1.7	15
83	Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation. International Journal of Molecular Sciences, 2017, 18, 1850.	4.1	16
84	Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention. Thrombosis and Haemostasis, 2017, 117, 457-470.	3.4	17
85	Use of bioresorbable vascular scaffold: a meta-analysis of patients with coronary artery disease. Open Heart, 2016, 3, e000462.	2.3	6
86	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. Platelets, 2016, 27, 687-693.	2.3	16
87	“Assessment of Endogenous Thrombolysis Predicts Cardiovascular Risk in Patient with ST-elevation Myocardial Infarction. Heart, 2016, 102, A69-A70.	2.9	1
88	Treatment of calcified coronary artery lesions. Expert Review of Cardiovascular Therapy, 2016, 14, 683-690.	1.5	14
89	Spontaneous Coronary Artery Dissection: The Phantom Menace. Cardiology Research, 2016, 7, 214-217.	1.1	1
90	Global Thrombosis Test “ a possible monitoring system for the effects and safety of dabigatran. Thrombosis Journal, 2015, 13, 39.	2.1	15

#	ARTICLE	IF	CITATIONS
91	Usefulness of Platelet Function Tests to Predict Bleeding With Antithrombotic Medications. Cardiology in Review, 2015, 23, 323-327.	1.4	5
92	Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Design, Development and Therapy, 2015, 9, 3801.	4.3	2
93	Platelet Function Tests: Why They Fail to Guide Personalized Antithrombotic Medication. Journal of the American Heart Association, 2015, 4, .	3.7	20
94	Rivaroxabanâ€”a safe alternative to warfarin in atrial fibrillation cardioversion. British Journal of Cardiac Nursing, 2015, 10, 41-43.	0.1	0
95	Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes. Open Heart, 2015, 2, e000258.	2.3	12
96	Endogenous Fibrinolysis. Journal of the American College of Cardiology, 2015, 65, 1683-1699.	2.8	93
97	PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Journal of Thrombosis and Thrombolysis, 2014, 38, 423-429.	2.1	18
98	Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thrombosis Research, 2014, 133, 919-926.	1.7	36
99	NOAC in Acute Coronary Syndrome and AF?. Cardiovascular & Hematological Disorders Drug Targets, 2014, 14, 154-164.	0.7	3
100	Platelet Function Tests in Clinical Cardiology. Journal of the American College of Cardiology, 2013, 61, 2115-2129.	2.8	74
101	Use of thrombectomy devices in primary percutaneous coronary intervention: A systematic review and meta-analysis. International Journal of Cardiology, 2013, 163, 229-241.	1.7	50
102	Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. European Heart Journal, 2013, 34, 354-363.	2.2	38
103	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
104	First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: Possible relationship to the â€œJapanese paradoxâ€œ. International Journal of Cardiology, 2011, 152, 43-48.	1.7	47
105	Prognostic Value of Plasma Fibrinolysis Activation Markers in Cardiovascular Disease. Journal of the American College of Cardiology, 2010, 55, 2701-2709.	2.8	102
106	Impaired Endogenous Thrombolysis in Acute Coronary Syndrome Patients Predicts Cardiovascular Death and Nonfatal Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 2107-2115.	2.8	73
107	Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugsâ€”fact or artifact?. Nature Reviews Cardiology, 2009, 6, 365-373.	13.7	54
108	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology, 2009, 6, 273-282.	13.7	90

#	ARTICLE	IF	CITATIONS
109	Coronary thrombosis: In vivo, ex vivo and in vitro. BMJ Case Reports, 2009, 2009, bcr0920080983-bcr0920080983.	0.5	1
110	The role of distal myocardial protection devices during percutaneous coronary interventions. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 52-59.	0.9	5
111	A Cautionary Tale. Journal of Clinical Neuromuscular Disease, 2005, 7, 25-28.	0.7	6
112	Distal Myocardial Protection During Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2005, 46, 1434-1445.	2.8	32
113	Global Thrombosis Test: Occlusion is attributable to shear-induced platelet thrombus formation.. TH Open, 0, 0, .	1.4	0
114	Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease. JAMA Cardiology, 0, , .	6.1	0